No Data
No Data
September 11th A-shares Lightning Rod | Henan Jindan Lactic Acid Technology: Guangzhou Chengxin, a shareholder, plans to reduce its shareholding by no more than 2.99%; ST Xulan: Stock trading may be subject to delisting risk warning.
Henan Jindan Lactic Acid Technology's shareholder, Guangzhou Chengxin, plans to reduce its shareholding by no more than 2.99%; Anfu Ce Link Limited's specific shareholders, Da Sheng Investment and He Sheng Investment, plan to jointly reduce their shareholding by no more than 1.65 million shares; Weide Information terminates the planning of major asset restructuring; Improve Medical Instruments' affiliated subsidiaries' business does not include human stem cell, gene diagnosis and treatment technology development and application; The special treat Xulan's stocks may be subject to delisting risk warning.
We Think That There Are More Issues For Anfu CE LINK (SZSE:300787) Than Just Sluggish Earnings
Anfu CE Link Limited (300787.SZ): The company can provide high-speed USB4 cables for AI/AR/VR glasses.
Anfu Ce Link Limited (300787.SZ) stated on the investor interactive platform that the company can provide high-speed cables for AI/AR/VR glasses with USB4 peripheral devices, as well as AOC USB4 cables for long-distance high-speed transmission.
Anfu Ce Link Limited: Summary of Half-Year Report in 2024.
Anfu Ce Link Limited: Half-year report for the year 2024.
Anfu Ce Link Limited (300787.SZ): Net income in the first half of the year was 33.2714 million yuan, a decrease of 50.73% year-on-year.
On August 19th, Gelunhui reported that Anfu Celink Limited (300787.SZ) released its 2024 semi-annual report, with a reported revenue of 0.938 billion yuan, an 8.57% year-on-year increase; net income attributable to shareholders of the listed company was 33.2714 million yuan, a year-on-year decrease of 50.73%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 30.4877 million yuan, a year-on-year decrease of 44.97%; and basic earnings per share were 0.1262 yuan. The company's research and development investment in the first half of 2024 was 104.8833 million yuan, an increase of 31.224 million yuan compared to the first half of 2023.
No Data
No Data